NimBio provides a remote monitoring platform that utilizes passive biosensing technology to continuously track inflammatory biomarkers in patients with Inflammatory Bowel Disease (IBD). This approach enables early detection of flare-ups, reducing hospitalizations and optimizing treatment through real-time therapeutic recommendations.
Funding
$880K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Managing Inflammatory Bowel Disease (IBD) is challenging due to the unpredictable nature of flare-ups, which can lead to hospitalizations. Traditional lab testing for inflammatory biomarkers is often infrequent and can be refused by patients, hindering continuous monitoring and early detection of these flare-ups. The lack of continuous monitoring results in delayed detection of IBD flares, increasing healthcare costs associated with hospitalizations.
Solution
NimBio offers a remote patient monitoring platform that utilizes a passive biosensing device, the Inflammometer™, to continuously track inflammatory biomarkers in IBD patients. The device collects data passively and provides real-time insights into a patient's inflammation status. The platform analyzes this data to identify the cause of flare-ups, such as treatment failure or poor adherence, and offers real-time therapeutic recommendations. By enabling early detection of flare-ups and personalized treatment adjustments, NimBio aims to reduce hospitalizations and improve the quality of life for IBD patients.
Target Audience
NimBio's primary customers include IBD patients seeking effortless and high-quality care, hospitals and physicians aiming to enhance care delivery, pharmaceutical companies focused on treatment optimization, and payers looking to reduce hospitalizations and disease complications.
Features
- Inflammometer™: A patient-friendly, non-invasive device for passive and continuous collection of biomarker data.
- Real-time inflammation status updates accessible to both patients and healthcare providers.
- Identification of flare-up causes, including treatment failure and medication non-adherence.
- Therapeutic recommendations delivered in real-time to optimize treatment plans.
- Clinical validation through completed and ongoing studies in multiple medical centers.
- Platform designed for short measurement times and affordability.